Healthcare Professionals

Do you want to talk to a medical expert about FLUCELVAX QUADRIVALENT? Our Medical Communications team can help.

Billing & Coding

2016-2017 NDC Carton: 70461-200-01

2016-2017 NDC Unit-of-Use: 70461-200-11

Presentation and Dose: Single-dose syringe

CPT Code: 90674 = Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic-free, 0.5 mL dosage, for intramuscular use

FLUCELVAX QUADRIVALENT Important Safety Information

Indication and Usage for FLUCELVAX QUADRIVALENT® (Influenza Vaccine)

FLUCELVAX QUADRIVALENT® is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUCELVAX QUADRIVALENT is approved for use in persons 4 years of age and older.

Important Safety Information
Contraindication
  • Do not administer FLUCELVAX QUADRIVALENT to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine.
Warnings & Precautions
  • Guillain-Barré Syndrome (GBS): If GBS has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX QUADRIVALENT should be based on careful consideration of the potential benefits and risks.
  • Preventing and Managing Allergic Reactions: Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
  • Syncope: Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUCELVAX QUADRIVALENT. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope by maintaining a supine or Trendelenburg position.
  • Altered Immunocompetence: After vaccination with FLUCELVAX QUADRIVALENT, immunocompromised individuals, including those receiving immunosuppressive therapy, may have a reduced immune response.
  • Limitations of Vaccine Effectiveness: Vaccination with FLUCELVAX QUADRIVALENT may not protect all vaccine recipients against influenza disease.
Most Common Adverse Reactions
  • The most common (≥10%) local and systemic reactions in adults 18-64 years of age were injection site pain (45.4%) headache (18.7%), fatigue (17.8%) and myalgia (15.4%), injection site erythema (13.4%), and induration (11.6%).
  • The most common (≥10%) local and systemic reactions in adults ≥65 years of age were injection site pain (21.6%) and injection site erythema (11.9%).
  • The most common (≥10%) local and systemic reactions in children 4 to < 6 years of age were tenderness at the injection site (46%), injection site erythema (18%), sleepiness (19%), irritability (16%), injection site induration (13%), and change in eating habits (10%).
  • The most common (≥10%) local and systemic reactions in children 6 through 8 years of age were pain at the injection site (54%), injection site erythema (22%), injection site induration (16%), headache (14%), fatigue (13%), and myalgia (12%).
  • The most common (≥10%) local and systemic reactions in children and adolescents 9 through 17 years of age were pain at the injection site (58%), headache (22%), injection site erythema (19%), fatigue (18%) myalgia (16%), and injection site induration (15%).

Please see accompanying US Full Prescribing Information for FLUCELVAX QUADRIVALENT.

Seqirus Vaccines maintains the FLUCELVAX QUADRIVALENT Pregnancy Registry for pregnant women immunized with FLUCELVAX QUADRIVALENT (Influenza Vaccine) during pregnancy. The Registry is strictly observational and is designed to collect prospective data on pregnancy outcomes. To enroll in the Registry, determine eligibility or for more information, please call 1-877-413-4759 or click here.